Increasing access to prescription hormone therapy.

HB 1971 requires health plans to provide reimbursement for a 12-month refill of covered prescription hormone therapy, obtained at one time, for their enrollees. This aims to increase access to these medications for patients of all ages. Starting January 1, 2026, health plans must comply, unless the enrollee requests a smaller supply, the provider instructs a smaller supply, or the therapy is a controlled substance. The 12-month supply applies to medications that can be safely stored at room temperature, while controlled substances must be covered for the maximum refill allowed by law. Prescription hormone therapy is defined as FDA-approved drugs that medically adjust hormone levels, excluding certain glucagon-like peptide-1 medications.